1,9-Dimethyl Methylene Blue Shows Photodynamic Activity in Oropharyngeal Carcinoma Models
A novel methylene blue derivative, 1,9-dimethyl methylene blue, shows promise as a photosensitizer for photodynamic therapy against oropharyngeal cancer.
By Sanare Lab · August 9, 2026 · 4 min read
Key Takeaway
A modified methylene blue derivative called 1,9-dimethyl methylene blue (DMMB) demonstrated concentration-dependent and light-dose-dependent photodynamic cytotoxicity against oropharyngeal carcinoma cells in laboratory models. This is an early preclinical study with no human data.
Photodynamic therapy (PDT) is a minimally invasive cancer treatment that uses light-activated drugs called photosensitizers to destroy tumor cells. When a photosensitizer accumulates in cancer tissue and is exposed to specific wavelengths of light, it generates reactive oxygen species (ROS) that kill nearby malignant cells while sparing healthy tissue.
A study published in Journal of Photochemistry and Photobiology B: Biology in August 2026 examined a modified methylene blue compound — 1,9-dimethyl methylene blue (DMMB) — for its photodynamic activity against oropharyngeal carcinoma cells.
Table of Contents
- What is photodynamic therapy?
- The DMMB photosensitizer
- Laboratory findings
- Limitations and next steps
- FAQ
- Shop Sanare Lab
- References
What is photodynamic therapy?
Photodynamic therapy (PDT) involves three components: a photosensitizing drug, a light source of the appropriate wavelength, and molecular oxygen in the tissue. The photosensitizer is typically administered systemically or applied locally. After a waiting period that allows the drug to accumulate preferentially in tumor tissue, the target area is illuminated with light. The excited photosensitizer transfers energy to oxygen molecules, generating singlet oxygen and other reactive oxygen species that damage cellular membranes, proteins, and DNA in the tumor.
PDT is already approved for several cancer types, including esophageal cancer, non-small cell lung cancer, and certain skin cancers. Researchers are continuously exploring new photosensitizers with improved optical properties, deeper tissue penetration, and higher selectivity for cancer cells.
This builds on a broader body of work — see our overview of methylene blue in experimental cancer models.
The DMMB photosensitizer
1,9-dimethyl methylene blue (DMMB) is a phenothiazine derivative related to methylene blue. Phenothiazine derivatives are well established as antimicrobial and anticancer photosensitizers. DMMB differs from standard methylene blue in the placement of two methyl groups, which may alter its membrane-binding properties, absorption spectrum, and reactive oxygen species generation efficiency.
The researchers investigated DMMB's molecular interactions with membrane-mimetic systems derived from human oropharyngeal carcinoma cells (HEp-2). These lipid-based models mimic the cell membrane environment and allow precise measurement of how the photosensitizer binds to and disrupts cancer cell membranes.
Laboratory findings
The study demonstrated that DMMB exhibited photodynamic cytotoxicity against oropharyngeal carcinoma cells in a concentration-dependent and light-dose-dependent manner. Higher concentrations of DMMB and increased light exposure both enhanced the killing of cancer cells. The researchers also characterized DMMB's membrane interactions, providing insight into the molecular basis of its photodynamic effect.
These findings position DMMB as a candidate photosensitizer for future PDT protocols targeting oropharyngeal carcinoma, a cancer type that includes cancers of the tonsils, base of the tongue, soft palate, and pharyngeal walls.
For the fundamentals, read our guide to methylene blue's properties, history and safety.
Limitations and next steps
This research is entirely laboratory-based. All experiments were conducted in vitro using cell lines and membrane models, not in animals or human patients. The safety, pharmacokinetics, optimal dosing, and clinical efficacy of DMMB in oropharyngeal cancer remain unknown. Significant additional preclinical and clinical development would be required before DMMB could be considered for human use.
If you are researching protocols, our protocol dosing calculator helps model a weight-based regimen.
Frequently Asked Questions
What is photodynamic therapy and how does it work?
Photodynamic therapy (PDT) is a treatment that uses a photosensitizer drug and a specific wavelength of light to generate reactive oxygen species (ROS) that destroy cancer cells. The drug is preferentially taken up by tumor tissue, and when activated by light, it produces toxic oxygen molecules that damage cell membranes, proteins, and DNA.
How is DMMB different from regular methylene blue?
1,9-dimethyl methylene blue (DMMB) is a chemically modified form of methylene blue with two additional methyl groups. This modification may alter its membrane-binding properties, light absorption characteristics, and ability to generate reactive oxygen species when exposed to light. DMMB is an experimental compound and is not the same as standard methylene blue used in clinical diagnostics.
Is photodynamic therapy with DMMB available for patients?
No. DMMB is an experimental photosensitizer that has only been tested in laboratory cell cultures. It has not undergone animal studies or human clinical trials. Standard methylene blue is approved for certain diagnostic and surgical uses, but not as a cancer photosensitizer in routine clinical practice.
Photodynamic therapy uses a special dye that becomes toxic to cancer cells only when a doctor shines a laser on it. 1,9-dimethyl methylene blue is a modified version of methylene blue that may work better as this light-activated dye. In laboratory tests, it killed oropharyngeal cancer cells in a dose-dependent manner when combined with light. This treatment has not been tested in human patients.
Shop Sanare Lab
Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.
Liquid drops, 60 ml (2 fl oz) — laboratory-grade methylene blue formulation.
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
- Membrane interactions and photodynamic activity of 1,9-dimethyl methylene blue in oropharyngeal carcinoma models. J Photochem Photobiol B. 2026; PMID: 42217302.
Medical Disclaimer
This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before making any health decisions. The research discussed is preclinical and has not been evaluated in human clinical trials.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.